title: MRI biomarkers for evaluation of treatment efficacy in preclinical diabetic retinopathy.
abstract: BACKGROUND
  One sober consequence of the current epidemic of diabetes mellitus is that an increasing number of people world-wide will partially or completely lose their sight to diabetic retinopathy. Clinically, the sight-threatening complications of diabetes are diagnosed and treated based on visible retinal lesions (e.g., dot-blot hemorrhages or retinal neovascularization). However, such anatomical microvascular lesions are slow to respond with treatment. Thus, there remains an urgent need for imaging biomarkers that are abnormal before retinal lesions are visibly apparent and are responsive to treatment.
  
  
  METHODS
  Here, the development of new MRI methods, such as manganese-enhanced MRI, for evaluating early diabetes-evoked retinal pathophysiology, and its usefulness in guiding new treatments for diabetic retinopathy are reviewed.
  
  
  CONCLUSIONS
  In diabetic retinopathy, not all important diagnostic and prognostic needs are well served by optical methods. In the absence of gross anatomy changes, critical times when drug intervention is most likely to be successful at reducing vision loss are missed by most light-based methods and thus provide little help in guiding diagnosis and treatment. For example, before clinical symptoms, is there an optimal time to intervene with drug therapy? Is a drug reaching its target? How does one assess optimal drug dose, schedule, and routes? How well do current experimental models mimic the clinical condition? As discussed herein, MRI is as an analytical tool for addressing these unmet needs. Future clinical applications of MRI can be envisioned such as in clinical trials to assess drug treatment efficacy, or as an adjunct approach to refine or clarify a difficult clinical case. New MRI-generated hypotheses about the pathogenesis of diabetic retinopathy and its treatment are discussed. In the coming years, a substantial growth in the development and application of MRI is expected to address relevant question in both the basic sciences and in the clinic.
authors.affiliation: Wayne State University, Department of Anatomy and Cell Biology, Detroit, MI, USA. baberko@med.wayne.edu
authors.forename: Bruce A
authors.initials: BA
authors.lastname: Berkowitz
authors.forename: David
authors.initials: D
authors.lastname: Bissig
authors.forename: Oliver
authors.initials: O
authors.lastname: Dutczak
authors.forename: Shannon
authors.initials: S
authors.lastname: Corbett
authors.forename: Rob
authors.initials: R
authors.lastname: North
authors.forename: Robin
authors.initials: R
authors.lastname: Roberts
mesh_terms: D000818:Animals; D015415:Biomarkers / Q000032:analysis; D003930:Diabetic Retinopathy / Q000175:diagnosis* / Q000628:therapy*; D004195:Disease Models, Animal; D006801:Humans; D008279:Magnetic Resonance Imaging / Q000379:methods*
chemical_list: D015415:Biomarkers